Stay updated on Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page
- Check4 days agoChange DetectedA new NIH funding entry for 2018 was added to the study's identifiers. This updates the record to reflect U.S. NIH support for KEYNOTE-799.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedThe page revision label changed from v3.6.4 to v3.6.5, signaling a minor update to the page's build. This does not modify the study details or other user-visible content.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check32 days agoChange DetectedRevision updated from v3.6.3 to v3.6.4, indicating a new version of the page’s documentation. This reflects an internal update to the page’s revision history rather than a substantive alteration to study details.SummaryDifference0.0%

- Check61 days agoChange DetectedRevision updated from v3.6.0 to v3.6.3, signaling a newer page revision. This update appears to be a maintenance/format change rather than a modification to study details or user-facing content.SummaryDifference0.0%

- Check75 days agoChange DetectedThe page now shows that no participants are being recruited and adds new sections to help readers read the study record, understand common questions, and learn how to join the study. It also includes a minor formatting change to the Intervention/Treatment label and updates the revision note to v3.6.0.SummaryDifference0.3%

- Check82 days agoChange DetectedThe page now displays a new revision label (v3.5.5) in the footer, replacing the previous v3.5.4. This indicates a minor internal update to the page rendering or maintenance.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab Combo in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Stage III NSCLC Clinical Trial page.